Skip to main content
. 2011 Dec 11;61(7):1045–1053. doi: 10.1007/s00262-011-1174-4

Table 1.

Description of patient cohort

Sex Age (years) Primary site Time to liver surgery (months) Synchronous cancer Number of metastasis Largest diameter (mm) CEA at liver surgery (μg/l) PGE2 at liver surgery (pg/ml) HLA-A2 status Disease-free survival (months) Overall survival (months) Status
F 40 Colon 8 Yes 7 75 1.426 205 ND 12 29 CRD
F 45 Rectum 6 Yes 5 50 0.9 487 Neg 8 AWD
F 45 Colon 4 Yes 9 22 17.3 411 Pos 23 AWD
F 61 Colon 1 Yes 2 22 5.1 42 Neg 4 AWD
F 61 Rectum 5 Yes 1 19 0.9 ND Pos FREE
F 63 Colon 13 No 1 16 16.6 602 Pos FREE
F 66 Colon 52 No 3 70 1.7 517 Neg 8 FREE
F 67 Rectum 7 No 1 17 3.4 350 ND FREE
M 44 Colon 6 Yes 5 10 1 353 Pos 6 NCRD
M 60 Colon 7 Yes 20a 13a ND 442 Neg AWD
M 62 Rectum 2 Yes 1 25 ND 173 Neg 7 AWD
M 64 Rectum 11 Yes 3 50 3.1 283 Pos 10 15 CRD
M 67 Colon 40 No 3 8 10.6 497 Neg 11 11 CRD
M 67 Colon 22 No 1 60 134 158 Neg 3 AWD
M 68 Colon 41 No 1 45 ND 297 Neg 1 AWD
M 72 Colon 25 No 1 18 2.4 397 Pos FREE
M 74 Rectum 4 Yes 4 32 3.4 583 Pos FREE
M 81 Colon 8 No 1 22 ND 345 Pos FREE

Clinical, histopathological and laboratory data on the eighteen patients with liver metastasis from CRC that were included in the study. Observation time was 18 months before outcome was assessed and classified as follows: CRD cancer-related death, NRCD non-cancer-related death, AWD alive with disease, FREE disease free at follow-ups. ND: CEA, PGE2 and HLA-A2 not determined in given patient. aDenotes inoperable patient; size and number of metastases were estimated by radiography